Alterity Therapeutics (ASX:ATH) raised about AU$2.1 million capital in the US via an at-the-market facility, according to a Monday Australian filing.
The company received the opportunity to raise the capital based on positive topline results from the phase two trial in multiple system atrophy for its ATH434 drug candidate, the filing said.
ATH434 is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, it added.
The company also expects to receive about AU$5.7 million in rebates from the Australian Taxation Office under the government's Research and Development Tax Incentive scheme.
The proceeds will allow it to advance its clinical and regulatory activities.
The firm's shares soared almost 17% in early trading on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。